Overlooked but Not Forgotten: Three Lesser-Known Reforms

Overlooked but Not Forgotten: Three Lesser-Known Reforms

The first anniversary of the federal health care law is drawing attention to its major changes. Here are three under-the-radar reforms that also will shape health care practice.

Whether it’s just another birthday or your Sweet Sixteenth, it’s never fun to be forgotten on a special day.

Of course, the federal health reform law has nothing to fear — at least not this year.

Hundreds of reform-related public events are taking place this month, with most tied to the first anniversary of the Patient Protection and Affordable Care Act being signed into law. The Obama administration this week scheduled a series of 42 events in 22 states, featuring six cabinet secretaries and other White House officials, in order to trumpet the law’s benefits. A coalition of progressive organizations, including small business groups and labor unions, are holding dozens of pro-PPACA events as well.

Not to be outdone, opponents of the federal health care law have scheduled a full slate of counterprogramming. Senate Republicans have prepared talking points focusing on problems associated with the reform law, such as still-rising insurance premiums. Several Washington, D.C.-based think tanks are hosting events that are critical of the law’s changes — and the Galen Institute even released a new book, “Why ObamaCare is Wrong for America.

Most recent coverage of PPACA continues to focus on the same core issues: the law’s sweeping changes to health coverage and the delivery system, how states are responding to new rules and the overhaul’s constitutionality.

However, PPACA’s sheer scope has ensured that — even a year later — there are some reforms that have been overlooked. Here are three changes that you may have missed.

1.) Investments in Public Health

Many analysts have keyed on the law’s delivery system and insurance reforms, but PPACA also made major investments in public health infrastructure, which some health care stakeholders have long found wanting.

An Institute of Medicine report sponsored by the Robert Wood Johnson Foundation and released last year concluded the United States lacks a “cohesive” national public health strategy. According to Dr. Clint MacKinney of the Rural Policy Research Institute, the U.S. has “probably been behind … [many other] developed countries” in terms of public health. Meanwhile, a recent report published in Disaster Medicine and Public Health Awareness  found that most state health departments are underprepared to respond to a major radiation emergency and insufficiently capable of handling the resulting health crisis — a topic of renewed importance given the nuclear scare unfolding in Japan.

The federal health law mandates spending $15 billion over 10 years in a Prevention and Public Health Fund. Speaking last year at the Alliance For Health Reform, MacKinney credited the law’s newly created National Prevention, Health Promotion of Public Health Council for establishing a structure to bring together senior government leaders to discuss public wellness priorities.

The law also commissioned the Public Health Service Ready Reserve Corps, a 6,500-member program that can be summoned to respond during national emergencies and public health crises. “I don’t think a lot of people realize it, [but the corps] is one of our uniformed branches of service” now, noted Timothy Jost, a health law professor at Washington and Lee University.

Meanwhile, state and local governments can apply for Community Transformation Grants, which could be used for initiatives like creating healthier school food options and improving workplace wellness.

2.) How ACOs Could Improve Behavioral Health

More than one in four adults suffer from mental illness, yet fewer than half get any kind of treatment for it, Kaiser Health News/Washington Post notes — and on the surface, PPACA may only worsen access to mental health care. 

Through the overhaul, more than 30 million U.S. residents are expected to gain insurance coverage within the decade, further weakening access to already-overbooked primary care providers. Meanwhile, mental health providers in various states are concerned that the programmatic growth will strain their dwindling resources. According to a National Alliance on Mental Illness report released this month, states have cut a total of $1.8 billion in mental health spending since 2009.

Weak reimbursement and rising volumes have driven many health care providers out of behavioral health care. One potential salve: PPACA’s creation of accountable care organizations, which could better reward providers for treating mental illness and offer “promising models for integration” of primary and behavioral health care, AIS Health notes.

For example, Mass.-based Harvard Vanguard Medical Associates and Neighborhood Health Plan have improved mental health care using an ACO-type environment. Specifically, a psychiatrist and therapist regularly sit with internists as patients present for routine appointments and other medical needs. According to Dr. Steven Adelman, who directs behavioral health and addiction medicine for Harvard Vanguard Medical Associates, patients’ wait time for behavioral health appointments has been sliced from weeks to “about 20 minutes now.” Meanwhile, Harvard Vanguard shares the funds it receives for traditional medical care with behavioral health clinicians.

3.) Shifts — and Still-Open Questions — in Biologic Regulations

Before PPACA, the United States lacked a formal process to approve generic versions of biologic drugs, which are created via biological processes instead of chemical ones. However, the law allows FDA to approve follow-on drugs that are clinically similar to current products on the market.

As part of the overhaul, the Biologics Price Competition and Innovation Act of 2009 specifically permits drug companies that create biologic products — which are produced via biological processes, rather than chemical ones — 12 years of exclusivity before a generic drugmaker can access the formula to make and sell biosimilar versions.

However, one health care lawyer notes that stakeholders remain locked in heated debate over the definition of exclusivity. According to Emily Strunk of Akin Gump Strauss Hauer & Feld, biologic drugmakers are pushing to clarify that the provision implies “data exclusivity” — specifically that competitors must wait 12 years after FDA approval before using data in the original formula when submitting their own filing. Meanwhile, generic manufacturers want FDA to specify that the agency meant “market exclusivity,” or that competitors must wait 12 years post-approval to begin marketing a generic version of the drug. According to Strunk, while exclusivity consistently favors the brand-name manufacturer, applying the term to data would significantly delay “generic versions of the brand-name … [which] would not even be ready for approval until long after the data exclusivity expired.”

FDA is currently weighing recommendations on how to finalize the term, and upcoming editions of “Road to Reform” will revisit this and other lesser-known provisions of PPACA. Meanwhile, here’s what else is making news on this anniversary week for health reform.

On the Hill

In the Courts

Analyzing the Overhaul

Rolling Out the Overhaul

In the States

Medical-Loss Ratio Rules

Exit mobile version